Eliem Therapeutics Debt to Equity Ratio 2021-2024 | CLYM
Current and historical debt to equity ratio values for Eliem Therapeutics (CLYM) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Eliem Therapeutics debt/equity for the three months ending June 30, 2024 was 0.00.
| Eliem Therapeutics Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.00B |
$0.22B |
0.02 |
| 2024-03-31 |
$0.00B |
$0.11B |
0.03 |
| 2023-12-31 |
$0.00B |
$0.11B |
0.03 |
| 2023-09-30 |
$0.00B |
$0.11B |
0.03 |
| 2023-06-30 |
$0.00B |
$0.11B |
0.03 |
| 2023-03-31 |
$0.01B |
$0.12B |
0.05 |
| 2022-12-31 |
$0.01B |
$0.13B |
0.05 |
| 2022-09-30 |
$0.01B |
$0.13B |
0.05 |
| 2022-06-30 |
$0.01B |
$0.14B |
0.06 |
| 2022-03-31 |
$0.01B |
$0.16B |
0.05 |
| 2021-12-31 |
$0.01B |
$0.17B |
0.04 |
| 2021-09-30 |
$0.01B |
$0.18B |
0.03 |
| 2021-06-30 |
$0.16B |
$-0.05B |
-3.12 |
| 2021-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
